Bluejay Diagnostics (BJDX) Short term Debt (2020 - 2021)
Bluejay Diagnostics (BJDX) reported Short term Debt of $2000.0 for Q4 2021, down 98.4% on a YoY basis from $125102.0 in Q4 2020, and down 98.26% sequentially from $115102.0 in Q3 2021.
Bluejay Diagnostics (BJDX) Short term Debt (2020 - 2021) Analysis & Trends
Bluejay Diagnostics (BJDX) has 2 years of Short term Debt data on file, last reported at $2000.0 in Q4 2021.
- For the quarter ending Q4 2021, Short term Debt fell 98.4% year-over-year to $2000.0; the trailing twelve-month figure through Dec 2021 stood at $2000.0 (down 98.4% YoY), and the FY2021 full-year result was $2000.0, down 98.4% from the prior year.
- Short term Debt fell to $2000.0 in Q4 2021, from $115102.0 in the prior quarter.
- In the past five years, Short term Debt ranged from a high of $125102.0 in Q4 2020 to a low of $2000.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - |
| 10 | Bluejay Diagnostics | 2,754.24 | 2,754.24 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 2,000.00 |
| Sep 30, 2021 | 115,102.00 |
| Dec 31, 2020 | 125,102.00 |